Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 2 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Author(s): Alexander Fanaroff Added: 1 year ago
ACC.24 — Dr Alexander Fanaroff (Penn Medicine, US) joins us onsite at ACC.24 to discuss the findings from the BE ACTIVE study, which investigated behavioural economic approaches to increasing physical activity (PA) in patients with an elevated risk of cardiovascular disease (NCT03911141).This randomized, controlled trial enrolled 1062 patients with a 10-year atherosclerotic cardiovascular risk… View more

Prevention & Chronic Conditions
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Joshua Stolker , Philippe Gabriel Steg , Roberta Rossini , et al Added: 1 month ago

COVID-19

MI/ACS
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 3 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 3 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Naveed Sattar , Philippe Gabriel Steg , Lale Tokgözoğlu , et al Added: 1 year ago
Watch this on-demand programme chaired by Prof Naveed Sattar (School of Cardiovascular and Metabolic Health, Glasgow, UK). Radcliffe Cardiology presents a distinguished panel of experts: Prof Gabriel Steg (University Institute of France, Paris, FR), Prof Lale Tokgozoglu (Hacettepe University, Ankara, TR), and Dr Joshua Stolker (St Louis Hospital, Missouri, US). This roundtable discussion explores… View more

Anticoagulation
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 6 months ago

Prevention & Chronic Conditions
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 1 month ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 3 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention